OP
OPRX
OptimizeRx Corp
$5.23
-0.95%
$98.1M
No data for this timeframe.
Vol
Market Cap$98.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders50 funds
Inst. Value$44.2M
Inst. Activity11 buys / 6 sells
SEC Reports6
Press Releases3
Recent Activity
Jun 12, 2026
SEC
OptimizeRx held its 2026 Annual Meeting on June 9, 2026. Shareholders approved an amendment to the 2021 Equity Incentive
8-K — Impact 3/10
Jun 11, 2026
SEC
In Q3 2025, three institutions (BofA, Schwab, RenTech) accumulated $3.3M in OPRX positions, while four sellers (Morgan S
INST-CLUSTER — Impact 4/10
Jun 9, 2026
Insider
WASSON GREGORY D was granted 34,517 shares
Director
Jun 9, 2026
Insider
Vos Ellen O'Connor was granted 34,517 shares
Director
Jun 9, 2026
Insider
Spangler Patrick D was granted 34,517 shares
Director
Jun 5, 2026
SEC
OptimizeRx disclosed the separation of Chief Commercial Officer Theresa Greco, effective June 15, 2026, with a separatio
8-K — Impact 3/10
Inst.
ROYCE & ASSOCIATES LP — ADD
888,030 shares ($5.6M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
216,856 shares ($1.4M)
Price Targets
$11.50
+119.9% upside
Strong Buy
Current $5.23
Low $7.00
Median $10.50
High $18.00
6 analysts
$7.00
$18.00
Analyst Ratings
4Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Lake Street | MAINTAIN | Buy → Buy |
| May 13, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
| May 13, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight → Equal-Weight |
| May 13, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Mar 6, 2026 | Lake Street | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.11 | $0.08 — $0.15 | -53% YoY | 5 |
| Next Q | $0.25 | $0.18 — $0.29 | 23% YoY | 5 |
| Current FY | $0.94 | $0.88 — $1.00 | -11% YoY | 5 |
| Next FY | $1.09 ▼ -2.3% | $0.94 — $1.27 | 16% YoY | 5 |
Latest Reports
NEUTRAL
8-K
3/10
OptimizeRx held its 2026 Annual Meeting on June 9, 2026. Shareholders approved an amendment to the 2021 Equity Incentive
Jun 12, 2026
MIXED
INST-CLUSTER
4/10
In Q3 2025, three institutions (BofA, Schwab, RenTech) accumulated $3.3M in OPRX positions, while four sellers (Morgan S
Jun 11, 2026
NEUTRAL
Press
4/10
OptimizeRx announced that DeepIntent will be the first DSP to integrate its proprietary EHR network into its healthcare
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $7.3M | — |
| ROYCE & ASSOCIATES LP | $5.6M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.3M | — |
| BLAIR WILLIAM & CO/IL | $3.9M | — |
| DIMENSIONAL FUND ADVISORS LP | $3.5M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | WASSON GREGORY | A | $0.00 |
| Jun 9, 2026 | Vos Ellen | A | $0.00 |
| Jun 9, 2026 | Spangler Patrick | A | $0.00 |
| Jun 9, 2026 | Presti Mariyamma | A | $0.00 |
| Jun 9, 2026 | Lang James | A | $0.00 |
50 institutional holders with $44.2M total value (7,001,108 shares) as of 2026-Q1. Top holders: BlackRock,, ROYCE, VANGUARD. Net buying activity: 11 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1,163,501 | $7.3M | 16.5% | — |
| 2 | ROYCE & ASSOCIATES LP | 888,030 | $5.6M | 12.6% | ADD +30.2% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 685,449 | $4.3M | 9.7% | — |
| 4 | BLAIR WILLIAM & CO/IL | 614,992 | $3.9M | 8.7% | — |
| 5 | DIMENSIONAL FUND ADVISORS LP | 563,570 | $3.5M | 8.0% | — |
| 6 | STATE STREET CORP | 477,780 | $3.0M | 6.8% | — |
| 7 | GOLDMAN SACHS GROUP INC | 358,443 | $2.3M | 5.1% | — |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 331,037 | $2.1M | 4.7% | — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 216,856 | $1.4M | 3.1% | DOUBLED +633.2% |
| 10 | D. E. Shaw & Co., Inc. | 142,923 | $897.6K | 2.0% | TRIM -64.8% |
| 11 | Trexquant Investment LP | 136,874 | $859.6K | 1.9% | — |
| 12 | Russell Investments Group, Ltd. | 125,493 | $788.1K | 1.8% | TRIM -56.6% |
| 13 | VANGUARD FIDUCIARY TRUST CO | 111,129 | $697.9K | 1.6% | — |
| 14 | SEI INVESTMENTS CO | 98,633 | $619.4K | 1.4% | ADD +83.4% |
| 15 | CREDIT AGRICOLE S A | 89,200 | $560.2K | 1.3% | — |
| 16 | Vanguard Global Advisers, LLC | 85,400 | $536.3K | 1.2% | — |
| 17 | RAYMOND JAMES FINANCIAL INC | 83,163 | $522.3K | 1.2% | — |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 82,072 | $515.4K | 1.2% | ADD +45.8% |
| 19 | ALLIANCEBERNSTEIN L.P. | 39,850 | $488.6K | 1.1% | — |
| 20 | MORGAN STANLEY | 76,368 | $479.6K | 1.1% | TRIM -53.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| ROYCE & ASSOCIATES LP | ADD | 682,030 | 888,030 | +30.2% | $5.6M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 29,578 | 216,856 | +633.2% | $1.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 289,060 | 125,493 | -56.6% | $788.1K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 53,789 | 98,633 | +83.4% | $619.4K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 164,592 | 76,368 | -53.6% | $479.6K | 2026-Q1 |
| FMR LLC | DOUBLED | 5,591 | 69,448 | +1142.1% | $436.1K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 53,094 | 68,494 | +29.0% | $430.1K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 31,495 | 42,705 | +35.6% | $268.2K | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 19,825 | 31,286 | +57.8% | $196.5K | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 16,284 | 24,166 | +48.4% | $151.8K | 2026-Q1 |
| RHUMBLINE ADVISERS | TRIM | 27,451 | 20,198 | -26.4% | $126.8K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 13,900 | 19,300 | +38.8% | $121.2K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 44,577 | 15,866 | -64.4% | $99.6K | 2026-Q1 |
| CWM, LLC | DOUBLED | 683 | 6,562 | +860.8% | $41.2K | 2026-Q1 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 8,051 | 1,284 | -84.1% | $8.1K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | NEAR_EXIT | 2,121 | 303 | -85.7% | $1.9K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 62 | 168 | +171.0% | $1.1K | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 213,298 | 289,060 | +35.5% | $3.5M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | TRIM | 321,051 | 112,867 | -64.8% | $1.4M | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 27,561 | 53,094 | +92.6% | $650.9K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 63,704 | 46,181 | -27.5% | $566.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 84,760 | 42,576 | -49.8% | $522.0K | 2025-Q4 |
| PRUDENTIAL FINANCIAL INC | TRIM | 86,485 | 31,495 | -63.6% | $386.1K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 107,900 | 29,578 | -72.6% | $362.6K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 21,327 | 28,903 | +35.5% | $354.4K | 2025-Q4 |
9 unique insiders with 11 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | WASSON GREGORY D | Director | AWARD | 34,517 | — | — |
| Jun 9, 2026 | Vos Ellen O'Connor | Director | AWARD | 34,517 | — | — |
| Jun 9, 2026 | Spangler Patrick D | Director | AWARD | 34,517 | — | — |
| Jun 9, 2026 | Presti Mariyamma Varghese | Director | AWARD | 17,258 | — | — |
| Jun 9, 2026 | Lang James Paul | Director | AWARD | 34,517 | — | — |
| Jun 9, 2026 | KLEMA CATHY | Director | AWARD | 34,517 | — | — |
| May 15, 2026 | Silvestro Stephen L | Chief Executive Officer | TAX W/H | 5,219 | $5.21 | $27.2K |
| May 15, 2026 | Greco Theresa | Chief Commercial Officer | TAX W/H | 914 | $5.21 | $4.8K |
| May 1, 2026 | Presti Mariyamma Varghese | Director | AWARD | 13,060 | — | — |
| Feb 11, 2026 | Odence-Ford Marion | Chief Legal & Admin Officer | EXERCISE | 4,000 | — | — |
| Feb 11, 2026 | Odence-Ford Marion | Chief Legal & Admin Officer | TAX W/H | 1,386 | $9.23 | $12.8K |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 2 mixed, 3 neutral. Avg impact: 4.5/10.
NEUTRAL
8-K
3/10
OptimizeRx held its 2026 Annual Meeting on June 9, 2026. Shareholders approved an amendment to the 2
Jun 12, 2026
MIXED
INST-CLUSTER
4/10
In Q3 2025, three institutions (BofA, Schwab, RenTech) accumulated $3.3M in OPRX positions, while fo
Jun 11, 2026
NEUTRAL
8-K
3/10
OptimizeRx disclosed the separation of Chief Commercial Officer Theresa Greco, effective June 15, 20
Jun 5, 2026
NEUTRAL
DEFA14A
3/10
OptimizeRx filed definitive additional proxy materials urging shareholders to vote FOR Proposal No.
Jun 1, 2026
MIXED
PRESS-RELEASE
6/10
OptimizeRx reported Q1 2026 revenue of $19.8M (down 10% YoY) and a GAAP net loss of $(0.5)M, but non
May 12, 2026
BULLISH
8-K
8/10
OptimizeRx reported strong 2025 financial results with record revenue of $109.4 million (up 19% YoY)
Mar 5, 2026
NEUTRAL
4/10
OptimizeRx announced that DeepIntent will be the first DSP to integrate its proprietary EHR network
May 21, 2026
BULLISH
8/10
OptimizeRx (OPRX) reported solid Q4 and full-year 2025 results with record revenue of $109.4M (+19%
Mar 5, 2026
BULLISH
8/10
OptimizeRx reported strong Q4 and full-year 2025 results with record revenue of $109.4M (+19% YoY),
Mar 5, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 4 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.50 mean target
+119.9% upside
Strong Buy (1.43)
$7.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $5.23 |
| Target Low | $7.00 |
| Target Mean | $11.50 |
| Target Median | $10.50 |
| Target High | $18.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.43) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.11 | $0.08 | $0.15 | -53.3% | — | 0↑ 1↓ | $0.0B | -30.8% | 5 |
| Next Q 2026-09-30 |
$0.25 | $0.18 | $0.29 | 23.0% | — | 0↑ 1↓ | $0.0B | -2.3% | 5 |
| Current FY 2026-12-31 |
$0.94 | $0.88 | $1.00 | -10.7% | -0.4% | 1↑ 0↓ | $0.1B | -11.0% | 5 |
| Next FY 2027-12-31 |
$1.09 | $0.94 | $1.27 | 16.0% | -2.3% | 0↑ 1↓ | $0.1B | 11.8% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.112 | |
| 7d ago | $0.103 | +0.009 |
| 30d ago | $0.000 | +0.112 |
| 60d ago | $0.000 | +0.112 |
| 90d ago | $0.168 | -0.056 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| May 13, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| May 13, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight | Equal-Weight |
| May 13, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Roth Capital | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | B. Riley Securities | REITERATE | Buy | Buy |
| Mar 6, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 6, 2026 | Stifel | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
other
OptimizeRx to Participate in Upcoming Investor Conferences
<p align="left">WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=VLdt-WWGU7pJ39atWiFP-gfJdvp1Q8
May 21, 2026
contract
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx’s Authenticated EHR Network
Powered by OptimizeRx’s new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers <
May 13, 2026
short_volume
Short Volume: OPRX — 62.3% short (0.7M / 1.1M)
Short: 695,753 | Exempt: 75,815 | TRF Vol: 1,116,372 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
<p align="center">– Q1 revenue totals $19.8 million<br>– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively<br>–
May 12, 2026
earnings_calendar
OPRX Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
other
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
Expands life sciences marketers’ reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx’s trusted EHR network for t
Apr 30, 2026
earnings_calendar
OPRX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 8, 2026
other
OptimizeRx Appoints Mary Varghese Presti to Board of Directors
Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational effic
Mar 25, 2026
short_volume
Short Volume: OPRX — 69.2% short (0.6M / 0.9M)
Short: 594,487 | Exempt: 900 | TRF Vol: 858,563 | Short Ratio: 69.2% | Off-exchange volume (dark pool + OTC)
Mar 5, 2026
earnings
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
<p align="justify">WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthc
Mar 5, 2026
earnings
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
<p align="justify">WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthc
Mar 5, 2026
earnings_calendar
OPRX Q4 2025 Earnings After Market Close — 2026-03-05